ClinicalTrials.gg
RecruitingNCT07778316DeLLphi-315Updated Sep 17, 2026

Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)

A Phase 3 interventional study of Tarlatamab in Small Cell Lung Cancer, sponsored by Amgen. Recruiting at 9 sites in 5 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 18 studies testing AMG 757 in Small Cell Lung Carcinoma — 9 open to participants now, 17 under way, 6 of them phase 3. AMG 757 · Small Cell Lung Carcinoma.

Planned enrollment
5th of 18
400 · median 221
Started
2026
with 5 others
Phase 3
6 of 18
2 open now
Primary completion
2027-09
later than 4 of 16 live
Registered
17th of 18
by date
Lead sponsor
11 of 18
Amgen

Among the 18 studies testing AMG 757 in Small Cell Lung Carcinoma, this one is the 5th largest by planned enrollment, is one of 6 that started in 2026, is one of 6 in phase 3, reaches primary completion later than 4 of the 16 other live ones, and was the 17th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 367 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

9 of the 18 studies testing AMG 757 in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About AMG 757

AMG 757: first FDA approval 2024 (IMDELLTRA), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Small Cell Lung Carcinoma studies recruiting now, 173 (66%) set no upper age limit and 67 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing AMG 757 in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

The primary objective of this study is to demonstrate non-inferiority in pharmacokinetic (PK) parameters of subcutaneous (SC) vs intravenous (IV) tarlatamab administration and to characterize the efficacy, safety, and tolerability of SC tarlatamab in participants with relapsed extensive-stage small-cell lung cancer (ES-SCLC) after platinum-based chemotherapy.

03

Conditions studied

  • Small Cell Lung Cancer

Keywords

  • Tarlatamab
  • ES-SCLC
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has provided prior to initiation of any study specific activities/procedures.
  • Age ≥ 18 years (or legal adult age within country, whichever is older) at the time of signing the informed consent.
  • or cytologically confirmed SCLC with demonstrated progression or relapse.
  • Participants who progressed or recurred following 1 platinum-based regimen.
  • as defined per 1.1 within the 21-day screening period.
  • (ECOG) PS of 0 or 1.
  • Minimum of 12 weeks.
  • Adequate organ function.
  • History of central nervous system (CNS) are allowed with considerations defined in the protocol.

Exclusion criteria

Exclusion Criteria:

Disease Related

- Any previous diagnosis of non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation that has transformed to SCLC, or mixed SCLC and NSCLC histology, with exceptions defined in the protocol.

Other Medical Conditions

  • Myocardial infarction and/or symptomatic congestive heart failure ( > class II) within 6 months prior to first dose of study treatment.
  • History of arterial thrombosis (e.g., stroke or ) within 6 months prior to first dose of study treatment.
  • Current evidence or history of non-infectious pneumonitis/ILD (interstitial lung disease) that required or other treatment.
  • History of other within the past 2 years, with exceptions defined in the protocol.
  • Presence or history of viral infection based on criteria per protocol.
  • History of solid organ transplantation.
  • Symptoms and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection requiring antibiotics within 7 days prior to the first dose study treatment.
  • Known sensitivity or a to any of the products or components.
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.

Prior/Concomitant Therapy

  • Prior systemic anticancer therapy within 30 days of enrolment
  • Prior history of severe or life-threatening events from any immune-mediated therapy.
  • Receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 14 days prior to first dose of study treatment.
  • Live and within 28 days prior to the start of study treatment.
  • Receiving another anticancer therapy for a malignancy other than SCLC.
  • More than 1 prior line of anticancer therapy for SCLC.
  • Participation in a tarlatamab clinical trial or prior therapy with any selective inhibitor of the delta-like ligand 3 (DLL3) pathway.
  • Treatment in an alternative trial within 28 days prior to enrolment.
  • History of allergy or to similar products (eg, drugs with a similar chemical structure or other monoclonal antibody) or any .

Other Exclusions

  • Participants unable to have SC injections administered in the abdomen or thigh.
  • Participant unlikely to be able to complete all protocol-required procedures, restrictions and requirements.
  • History or evidence of any other disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to participant safety.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Tarlatamab SC

    Participants will receive Tarlatamab via SC injection

    Drug: Tarlatamab

  • Active comparator
    Tarlatamab IV

    Participants will receive Tarlatamab via IV infusion

    Drug: Tarlatamab

Interventions

  • Administered via SC injection or IV infusion

    Also known as: AMG 757, IMDELLTRA

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Cycle 2 Day 1 to Day 15 (AUC C2D1-D15) of Tarlatamab

    Time frame: From Cycle 2 Day 1 to Day 15 (each cycle is 28 days)

  2. Predose Concentration (Ctrough) of Tarlatamab

    Time frame: On Cycle 2 Day 15 (each cycle is 28 days)

Secondary outcomes

  1. Objective response (OR) per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)

    Time frame: Up to approximately 4 years

  2. Progression free survival (PFS) per RECIST v1.1

    Time frame: Up to approximately 4 years

  3. Duration of response (DOR) per RECIST v1.1

    Time frame: Up to approximately 4 years

  4. Disease control (DC) per RECIST v1.1

    Time frame: Up to approximately 4 years

  5. Overall survival (OS)

    Time frame: Up to approximately 4 years

  6. Number of participants with treatment-emergent adverse events (TEAEs) and Treatment-related Adverse Events (TRAEs)

    Time frame: Up to approximately 4 years

  7. Change from Baseline in Visual Analogue Scale (VAS) score of the EuroQol5 Dimension (EQ-5D-5L)

    Time frame: Up to approximately 4 years

  8. Responses to Patient-Reported Adverse Events Questionnaire (PRO-CTCAE)

    Time frame: Up to approximately 4 years

  9. Responses to Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire on symptom bother

    Time frame: Up to approximately 4 years

  10. Responses to Therapy Administration Satisfaction Questionnaire (TASQ)

    Time frame: Up to approximately 4 years

  11. Number of Participants with Anti-tarlatamab Antibody Formation

    Time frame: Up to approximately 4 years

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.

Of 56 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 12 months is below that.

Counting every sponsor, half of 69 studies reached it within 44 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2026
First posted
Aug 21, 2026
StartActual
Aug 28, 2026
Primary completionEst.
Sep 24, 2027
CompletionEst.
Jul 30, 2030
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07778316
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 21, 2026
Start date
Aug 28, 2026
Primary completion
Sep 24, 2027 (estimated)
Completion
Jul 30, 2030 (estimated)
Last update
Sep 17, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AMG 757

Start the discussion